Khaberni - Pfizer announced the death of a patient who was receiving HemPavzi treatment for blood thinning as part of a long-term study after experiencing serious side effects.
The European Hemophilia Consortium, a patient support group, stated that the patient died on December 14th after suffering a stroke followed by brain hemorrhage.
The patient was enrolled in a study testing the HemPavzi drug on patients with either type "A" or "B" blood-thinning disorders, with or without inhibitors.
In a statement, the company said, "Pfizer is actively working with the authority responsible for investigating the trial and the independent external data monitoring committee to gather information to better understand the complex and multifactorial circumstances surrounding this incident."
The treatment, which is administered via an injection once a week, was approved last year in the United States to prevent or reduce bleeding episodes in patients with either type "A" or "B" blood-thinning disorders, aged 12 and above, by targeting blood clotting proteins.
The company said that it does not anticipate any impact on the safety of patients who were treated with the medication based on current knowledge and the comprehensive clinical data collected so far.
